PATENT CLAIM ANALYSIS

Application Number: 15924881
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "415000"]

Abstract:
The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T max  value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T max  substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Claim (Index 30):
The method as claimed in  claim 28 , wherein said salt is added either externally or formed in-situ during the preparation of the composition.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.94915
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15434814', '12817740', '14925564', '12645376', '13893219']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8347855426387794
- 35 USC 102 Novelty (BERT): 0.5558397052255716
- Combined Prediction Score: 0.8068909588974585
- Mean Citation Score: 451.63926
- Max Citation Score: 580.65356
- Similarity Product: 280.30822102252245

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test